The impact of SGLT2-inhibitor therapy on platelet function in type 2 diabetes mellitus

Aim: We consider mean platelet volume (MPV), a pointer of activity related to type 2 diabetes mellitus (T2DM) and vascular complications, may have role in patients using Sodium-Glucose Co-Transporter inhibitors (SGLT2i). Therefore, we aimed evaluate the MPV change after SGLT2i use diabetic patients.Matherial Method: Hemogram parameters such as hemoglobin, hematocrit, 0th 24th weeks 102 with T2DM that received treatment added their existing medications control group which participants are compatible terms age gender factor were compared.Results: A significant increase was observed values hemoglobin (9.3 (8.2-10.3) 10.1±1.3, p<0.001, 13.9±1.42 14.4±1.5 respectively). Similarly, hematocrit value increased (42±3.7 44.2±3.8, p<0.001). There also both red blood cell (RBC) counts (5±0.42 5.2±0.47, 252,000 (209,000-304,000) 262,000 (221,000-322,000), p=0.007, No correlation identified between factors, duration, body mass index (BMI), fasting postprandial glucose, insulin use.Conclusion: Contrary studies analyzing relation its detected 24-week led an value.